Top 50 Health Care Startup Investors in China (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
117 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$134M |
|
BioVenture
VC Fund
|
72 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3.8M–$73M |
|
HSG
VC Fund
|
55 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
Med-Fine Capital
VC Fund
|
50 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.8M–$60M |
|
Lilly Asia Ventures
VC Fund
|
44 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$308M |
|
Frees Fund
VC Fund
|
43 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $425k–$35M |
|
IDG Capital
VC Fund
|
43 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $3M–$310M |
|
Matrix Partners China
VC Fund
|
43 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Artificial Intelligence | $2.8M–$137M |
|
Legend Capital
VC Fund
|
43 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$200M |
|
Highlight Capital
VC Fund
|
40 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $2.8M–$84M |
|
Shenzhen Capital Group
VC Fund
|
38 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Software | $1.6M–$156M |
|
Puhua Capital
VC Fund
|
37 | China, United Kingdom, United States | Series A, Series B, Seed | Health Care, Medical, Manufacturing | $1.4M–$103M |
|
Northern Light Venture Capital
VC Fund
|
36 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.3M–$100M |
|
Kaitai Capital
VC Fund
|
36 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Pharmaceutical | $1.4M–$57M |
|
BioTrack Capital
VC Fund
|
33 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
Dalton Venture
VC Fund
|
33 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $450k–$50M |
|
Cowin Capital
VC Fund
|
32 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$51M |
|
Legend Star
VC Fund
|
32 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Biotechnology | $425k–$52M |
|
Marathon Venture Partners
VC Fund
|
31 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.4M–$142M |
|
Lenovo Capital and Incubator Group (LCIG)
VC Fund
|
30 | China, Hong Kong, United States | Series A, Seed, Series B | Manufacturing, Artificial Intelligence, Software | $1.5M–$150M |
|
Shanghai Biomedical Industrial Equity Investment Fund
VC Fund
|
30 | China, United States, Hong Kong | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $8M–$159M |
|
CD Capital
VC Fund
|
29 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Longpan Investment
VC Fund
|
28 | China, United States, Cayman Islands | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $14M–$60M |
|
Sherpa Healthcare Partners
VC Fund
|
28 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7.2M–$128M |
|
Prox Ventures
VC Fund
|
26 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$28M |
|
Cowin Venture
VC Fund
|
26 | China, United States, Hong Kong | Series A, Angel, Series B | Health Care, Medical, Biotechnology | $425k–$257M |
|
CDH Investments
VC Fund
|
26 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $7.3M–$220M |
|
Taiyu Investment
VC Fund
|
25 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $4.1M–$29M |
|
Jan Hammer
Angel
|
24 | China, United States, France | Series A, Series B, Seed | Health Care, Medical, Medical Device | $2.8M–$231M |
|
Addor Capital
VC Fund
|
24 | China, Hong Kong, Singapore | Series A, Series B, Seed | Manufacturing, Semiconductor, Electronics | $1.4k–$47M |
|
Huagai Capital
VC Fund
|
24 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $425k–$147M |
|
Share Capital
VC Fund
|
23 | China, United States, Colombia | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $142k–$93M |
|
Oriza Holdings
VC Fund
|
23 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $1.7M–$200M |
|
Green Pine Capital Partners
VC Fund
|
23 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Biotechnology, Health Care | $425k–$150M |
|
Tiantu Capital
VC Fund
|
23 | China, United States, Japan | Series A, Series B, Seed | Food and Beverage, E-Commerce, Health Care | $1.4M–$142M |
|
Sinovation Ventures
VC Fund
|
22 | China, United States, Singapore | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1M–$110M |
|
Pan-Lin Capital
VC Fund
|
22 | China, United States, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $1.4k–$58M |
|
Gaorong Capital
VC Fund
|
21 | China, United States, Hong Kong | Series A, Series B, Seed | Information Technology, Software, Artificial Intelligence | $2.8M–$110M |
|
TF Capital
VC Fund
|
21 | China, United States | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$1.4B |
|
EFung Capital
VC Fund
|
21 | China, United States, India | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $1.4M–$100M |
|
Lotus Lake Ventures
VC Fund
|
21 | China, India | Series A, Series B, Seed | Medical, Health Care, Biotechnology | $42k–$97M |
|
Oriza Seed Capital (Oriza Yuandian)
VC Fund
|
21 | China, United States, Singapore | Series A, Seed, Angel | Manufacturing, Health Care, Medical | $213k–$60M |
|
Shunwei Capital
VC Fund
|
20 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.4M–$130M |
|
ZhenFund
VC Fund
|
19 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Software, E-Commerce | $425k–$23M |
|
Volcanics Venture
VC Fund
|
19 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Artificial Intelligence, Biotechnology | $350k–$60M |
|
Plum Ventures
VC Fund
|
19 | China, United States, Hong Kong | Series A, Angel, Seed | E-Commerce, Manufacturing, Software | $425k–$28M |
|
K2VC
VC Fund
|
19 | China, United States, Japan | Series A, Seed, Angel | E-Commerce, Manufacturing, Biotechnology | $425k–$50M |
|
Sinopharm Capital
VC Fund
|
19 | China, United States, Canada | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $1.4M–$114M |
|
Oriental Fortune Capital
VC Fund
|
19 | China, United States | Series A, Series B, Seed | Software, Manufacturing, Information Technology | $1.4M–$100M |
|
CASH Capital
VC Fund
|
18 | China, United States | Series A, Series B, Series C | Health Care, Manufacturing, Biotechnology | $1.4M–$113M |
| Access all 4951 investors in China Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 898
- Round size: Series A $5M–$67M; Series B $9.4M–$100M; Series C $15M–$134M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Guangjing Energy — Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.
- Talaris Therapeutics — Talaris seeks to help kidney transplant recipients and patients suffering from severe auto-immune diseases to live healthy lives free from chronic immunosuppression
- Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 171
- Round size: Seed $7.9M–$41M; Series A $3.8M–$47M; Series B $7.1M–$73M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Dami&Xiaomi — Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information.
- CART Medical — CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $2.8M–$40M; Series B $11M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $69M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 221
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- Abogen Biosciences — Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 216
- Round size: Seed $1.4M–$14M; Angel $425k–$14M; Series A $1.4M–$35M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $130M in 2015
Portfolio highlights
- SoundAI — Sound Technology is a science and technology innovation company that specializes in acoustics frontier technology and artificial intelligence interaction. It is committed to lead the more interactive experience of artificial intelligence in the real environment and realize the human-computer interaction vision that "listen to you and know whatyou think".
- Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
- Mask Network — Your Portal To The New, Open Internet.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 826
- Round size: Series A $3M–$122M; Series B $8.5M–$142M; Series C $15M–$310M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
- Bivision — Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
- Youxi Film Hotel — Youxi Film Hotel which is a hotel in China that combines the perfect combination of hotel and movie IP. It is also a movie hotel theme, combining film derivative industry, movie theme social space and film shooting. An integrated creative culture complex; dedicated to creating a Chinese-style movie and hotel cross-border experience hotel, breakingthrough the traditional overnight function of a traditional hotel, creating the ultimate movie experience for young people with a mindset.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 499
- Round size: Seed $2.8M–$98M; Series A $3M–$61M; Series B $10M–$137M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Lexin — LexinFintech Holdings is an online consumer finance platform for educated young adults in China. As one of China's leading financial technology companies, Lexin integrates its e-commerce-driven installment finance platform, Fenqile, with advanced risk management technologies, the Company's Dingsheng online investment platform, and theCompany's Juzi Licai online investment platform for individual investors, to create a comprehensive consumer finance ecosystem. The Company utilizes technologies including big data, cloud computing and artificial intelligence to enable the near-instantaneous matching of user funding requests with offers from the Company's more than 30 funding partners, which include commercial banks, consumer finance companies, and other licensed financial institutions. By serving the credit needs of China's educated young adults, Lexin helps its more than 20 million registered users to enjoy a better quality of life through the use of better credit.
- Huangbaoche — Huangbaoche is a travel service providing tour packages and booking services. Huangbaoche has over 100,000 Chinese-speaking drivers and tour guides providing airport pick-up services, chartered car services, and guided tours in over 1,500 overseas travel destination cities in 80 countries.
- Nuance Biotech — Nuance Biotech is a pharmaceutical company Based In China.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 427
- Round size: Series A $2.9M–$100M; Series B $12M–$115M; Series C $15M–$200M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/7a5aSCUfnr https://t.co/x14hb3jO7O
- Pony.ai — Pony.ai is a startup that builds full-stack autonomous driving solutions. It is a pioneer in autonomous mobility technologies and services across the US and China, spearheading public-facing Robotaxi pilots in both markets. Pony.ai is committed to creating a safe and sustainable mobility future by delivering autonomous mobility everywhere.Thecompany was founded by James Peng and Tiancheng Lou in 2016 and is headquartered in Fremont, California, United States.
- Jinqirui Biology — Jinqirui Biology is a biotechnology company that focuses on the research and development, manufacturing, production & sales of vitro diagnostics equipment and reagents.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 172
- Round size: Seed $10M–$84M; Series A $2.8M–$74M; Series B $7.6M–$70M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Approaching.AI — Approaching.AI is an AI Infra company focusing on the important large model application scenarios such as RAG.
- PoShell Robotics — PoShell Robotics is a general-purpose home robot, aiming to create a home-friendly and structurally stable robot.
- Xingyuan Zongheng Network Technology — Beijing Xingyuan Zongheng Network Technology is an aerospace and satellite internet enterprise. The company focuses on high-tech satellite system development, constellation networking, and commercial operations.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 533
- Round size: Series A $1.6M–$156M; Series B $14M–$142M; Series C $4.3M–$156M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Show more...Investment focus
- Industry: Health Care, Medical, Manufacturing
- Stage:Series A, Series B, Seed
- Geography: China, United Kingdom, United States
Investor stats
- Total investments: 257
- Round size: Seed $2.3M–$29M; Series A $1.4M–$42M; Series B $2.8M–$103M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- XY TECH — Energy
- Ganzhicao Technology — Gancao Doctor is an internet-based Traditional Chinese Medicine (TCM) company that helps clinics modernize their digital management and optimize operations. By using AI-assisted features, it enhances doctors' diagnostic and treatment abilities, delivering valuable benefits to doctors, patients, and clinics.
- Interstellar Lightyear — Interstellar Lightyear Technology is a developer specializing in dexterous robotic hands, focusing on creating intelligent dexterous hands with advanced capabilities for precise manipulation.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 274
- Round size: Seed $1.3M–$100M; Series A $4.3M–$67M; Series B $11M–$62M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 146
- Round size: Seed $2.4M–$20M; Series A $1.4M–$35M; Series B $10M–$57M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Aoquan — Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs.
- Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
- Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 93
- Round size: Seed $16M–$168M; Series A $14M–$45M; Series B $15M–$147M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
- LaNova Medicines — LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 142
- Round size: Seed $450k–$5M; Series A $2.8M–$17M; Series B $2.8M–$50M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
- NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 327
- Round size: Seed $1.4M–$20M; Series A $4.3M–$51M; Series B $2.8M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
- Huachen Core Light — Huachen Core Light is a semiconductor technology company that produces and manufactures optical communications and laser chips.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 156
- Round size: Seed $1.4M–$19M; Angel $425k–$49M; Series A $1.4M–$52M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — raised $109M in 2018
Portfolio highlights
- Yuanhao Power — The primary focus of Yuanhao Power, an AI native technology developer, is the creation of fifth-generation multimodal 4D world model base models. It creates a cohesive model system that encompasses dynamic environment reconstruction, generation, simulation, and intelligent agent training, and it encourages its use in applications like autonomousdriving, medical procedures, games and movies, and embodied intelligence. For the era of physical AI, it is dedicated to developing a universal world model base.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.4M–$16M; Series B $14M–$142M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Lenovo Capital and Incubator Group is an accelerator and venture capital firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Software
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 302
- Round size: Seed $1.5M–$29M; Series A $1.5M–$74M; Series B $8M–$150M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $500M in 2016
Portfolio highlights
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- SenseTime Medical — SenseTime Medical promotes the development and implementation of its medical big model and provides smart health solutions.
- Shenzhen Urban Transport planning Center — Shenzhen Urban Transport planning Center provides traffic information engineering and technical services in China.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 68
- Round size: Seed $8M–$50M; Series A $14M–$43M; Series B $14M–$159M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- BioGeometry — Reshaping the world, one protein at a time
- Surgerii Technology — Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design andintegration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.
- Beyond Therapeutics — Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 73
- Round size: Seed $1.4M–$15M; Series A $1.4M–$32M; Series B $7.1M–$34M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
- CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 43
- Round size: Seed $14M–$60M; Series A $14M–$30M; Series B $14M–$37M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Jingling Zhikang — Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics.
- Hanyue New Materials — Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 102
- Round size: Series A $7.2M–$50M; Series B $15M–$100M; Series C $12M–$128M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Shenfu Jianxing — Shenfu Jianxing is a brain-computer interface developer. It focuses on minimally invasive implanted brain-spinal interface technology, with "minimally invasive + low latency + high integration" as its core, to build implantable brain-spinal neural stimulation systems.
- Yosemite Clinic — Yosemite Clinic is a full-service clinic providing convenient walk-in medical services in a state-of-the-art environment in Central Pudong. They offer family medicine, internal medicine, surgery, orthopedics (sports medicine), dermatology, medical cosmetology, dentistry, gynecology, pediatrics, ophthalmology, anesthesiology, rehabilitationmedicine, medical imaging, laboratory, pharmacy and more. Their onsite facilities and equipment include CT, X-ray, Ultrasound, Laboratory and Operating Rooms. Their doctors come from China and across the world, enabling us to serve you in many languages including, English, Japanese, Malay, Mandarin Chinese and Cantonese.
- Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 81
- Round size: Seed $2.5M–$14M; Series A $2.8M–$28M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Angel, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 104
- Round size: Angel $425k–$1.4M; Series A $1.4M–$25M; Series B $2.8M–$257M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- CytoChip — Our journey began with a research project to develop a portable blood cell testing device for astronauts on space missions. Today, we are bringing that cutting-edge technology down to Earth to transform point-of-care diagnostics, from hospitals and clinics to pharmacies and home care. After nine years of development, CytoChip’s first product,CitoCBC®, is ready for launch. Using just one drop of blood, CitoCBC® delivers lab-quality CBC results within minutes, offering accuracy comparable to central laboratory analyzers at the point of care.At our core, we are a team of passionate engineers and scientists spanning two continents, united by a singular goal: to make reliable, affordable diagnostics accessible to more people worldwide. Our headquarters and R&D centerare located in California, USA, while our engineering and manufacturing center is based in Suzhou, China. We collaborate closely with leading U.S. hospitals to advance clinical validation and innovation.Starting with the world’s first CLIA Waived cartridge-based CBC, we are committed to tackling the toughest innovation challenges in point-of-care testing. Our mission is to empower healthcare providers with reliable, cost-effective diagnostics and make data-driven testing more accessible to patients and consumers.
- Genta Kyushu Bio — Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies.
- StringMotion Future — StringMotion Future focuses on the core technology research and development of tendon-inspired chord-driven robots, creating advanced robotic systems designed to deliver greater flexibility, precision, and efficiency for industrial and intelligent automation applications.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 298
- Round size: Series A $7.3M–$100M; Series B $14M–$142M; Series C $30M–$220M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- HitGen — HitGen is provides biological reagents and services to support drug discovery research.
- PaXini Tech — All Scenario Application—Haptic Digitization and Tactile Technology
- Eyegood Ophthalmic Hospital — Eyegood Ophthalmic Hospital is a ophthalmology hospital.
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 43
- Round size: Seed $4.1M–$20M; Series A $13M–$29M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Immunocan — JAWA138 memimpin di garis depan Inovasi Sistem Permainan Digital dengan fokus pada transparansi dan keadilan, terutama melalui Mekanisme RTP (Return to Player) yang Akurat.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
Jan Hammer is the partner at Index and the Board observer of Harmonic. Jan attended Oxford University.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States, France
Investor stats
- Total investments: 113
- Round size: Seed $2.8M–$15M; Series A $2.8M–$35M; Series B $14M–$231M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Transak — Transak offers a simple integration to allow your users to buy more than 100+ cryptocurrencies with credit/debit cards, or bank transfers in more than 120+ countries.
- Yuetong Eye Clinic — Yuetong Eye Clinic is a medical institution that provides myopia surgery for adults and myopia prevention and control for adolescents. It is a medical institution focusing on adult myopia surgery and adolescent myopia prevention and control.
- Xiwei Biotechnology — Xiwei Biotechnology is an ophthalmology implanted medical device developer that specializes in the unique product development of new bio-modified materials for ocular implantable medical devices and regenerative medicine.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 344
- Round size: Seed $1.4k–$14M; Series A $1.6M–$43M; Series B $13M–$47M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Beta Infinite — Beta Infinite approaches data and model technologies in a distinctive and distinctive way.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 143
- Round size: Angel $425k–$15M; Series A $1.4M–$67M; Series B $3.5M–$147M
- Lead/follow: 43% lead, 57% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
- GigaAI — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
- Falcon Technology — Falcon Technology focuses on DSA processor design innovation, developing a dedicated computing technology ecosystem based on the RISC-V architecture to deliver high-performance, energy-efficient processing solutions for next-generation intelligent computing applications.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 205
- Round size: Series A $1.7M–$55M; Series B $10M–$100M; Series C $14M–$200M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- ChipSine — ChipSine is an Integrated Circuit (IC) design company that focuses on the research and development of automotive-grade electronic control chips.
- Empower — Empower is an enterprise platform focused on intelligent laser manufacturing that makes lasers smart.
- Neowise — XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Health Care
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 206
- Round size: Angel $425k–$7.4M; Series A $1.4M–$92M; Series B $14M–$150M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $138M in 2019
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
- Canchen Technology — Canchen Tech is a technology company that focuses on the research and development of cell engineering technology in the life sciences field .The company has developed a system-level virtual organ spatiotemporal dynamic evolution model to construct a cross-scale digital twin system for life data. The platform simulates dynamic interactions frommolecules, cells, tissues to organs, and uses algorithms to simulate and deduce evolutionary processes. Its core business is used for preclinical developmental toxicity evaluation of new drugs, target discovery for rare diseases, and early screening of newborn diseases. This technical approach aims to replace and reduce some traditional in vivo animal experiments through data feedback and virtual simulation.
Tiantu Capital is a venture capital association.
Show more...Investment focus
- Industry: Food and Beverage, E-Commerce, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, United States, Japan
Investor stats
- Total investments: 139
- Round size: Seed $7M–$20M; Series A $1.4M–$16M; Series B $10M–$142M
- Lead/follow: 52% lead, 48% follow
- Last fund: May invest from a new fund soon — raised $68M in 2019
Portfolio highlights
- LAN — LAN is a natural skincare company that offers skin care cosmetics.
- Zdeer — Zdeer is a health tech brand focusing on artificial intelligence health and consumer medicine. It is committed to improving the health awareness of the whole people, while breaking the shackles of the traditional health industry, through continuous technological innovation and product innovation, to bring better-looking and better-use products toconsumers at a more affordable price.
- Billy Information — Mycooltv leverage advanced AI technology to create cost-effective solutions for premium hotel experiences. AI travel media network.
Sinovation Ventures is a full-service venture capital firm that actively invests in the Chinese technology market.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 284
- Round size: Seed $1M–$14M; Series A $1.4M–$28M; Series B $10M–$110M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $203M in 2022
Portfolio highlights
- ImageDT — ImageDT is a Enterprise services company.
- Gestala — Gestala is China’s first pioneer in ultrasound-based Brain-Computer Interface (BCI). We are dedicated to engineering a platform with full-brain read-write capabilities, offering transformative therapeutic modalities for neurological disorders. Beyond clinical impact, we aim to decode the neural code and pave the way for a symbiotic future wherebrain science and artificial intelligence converge.
- Jiangxian Technology — Jiangxian Technology is a company focused on embodied intelligence, a field that integrates artificial intelligence with physical systems such as robots and smart devices, enabling machines to perceive, learn from, and interact with the real world in a more human-like and adaptive manner across applications like automation, healthcare, and advancedmanufacturing.
Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 82
- Round size: Seed $1.4k–$28M; Series A $297k–$37M; Series B $7.1M–$58M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Lingdong Core Optics — Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips.
- UniXell Biotechnology — Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 291
- Round size: Seed $4.1M–$62M; Series A $2.8M–$75M; Series B $14M–$110M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2020
Portfolio highlights
- Genta Kyushu Bio — Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies.
- Cascade — Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation.
- Mochi Intelligence — Mochi Intelligence is a high-tech enterprise specializing in the research and development of embodied intelligent robots. The company is committed to creating intelligent robots including humanoid robots that can truly understand and adapt to the real world through cutting-edge artificial intelligence technology and robotics.
TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 63
- Round size: Series A $10M–$120M; Series B $11M–$110M; Series C $7M–$1.4B
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- QL Biopharma — QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases.
- Vivatides Therapeutics — Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
- Angitia Biopharmaceuticals — Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 82
- Round size: Series A $1.4M–$36M; Series B $14M–$100M; Series C $14M–$74M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
- Heluo New Image — Heluo New Image is a cell treatment platform developer that focuses on iPSC directed differentiation, gene editing, large-scale cell product production, and cell therapy technology development.
- Xgene Pharmaceutical — Xgene Pharmaceutical is a pharmaceutical company.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Lotus Lake Ventures is an investment firm committed to investing in science and technology innovation enterprises, focusing on high-tech and high-tech enterprises with core competitiveness in the initial stage and growth stage..
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, India
Investor stats
- Total investments: 78
- Round size: Seed $42k–$72M; Series A $709k–$97M; Series B $2M–$40M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Zhitong Technology — Zhitong Medical is a provider of computational imaging technology that focuses on the development of surgical vision.
- Fulinlan Technology — Fulinlan is committed to the planning, design, development, structural analysis, equipment processing and installation of non-standard proprietary equipment, precision parts and other products in the field of aerospace.
- Torrey Pines Medicine — Torrey Pines Medicine is a biotechnology business focused on creating next-generation ultra-long-acting peptide therapies for metabolic illnesses.
Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 149
- Round size: Seed $213k–$25M; Angel $425k–$14M; Series A $1.4M–$60M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Youshu Quantum — Youshu Quantum is a deep-tech startup specializing in quantum computing software, middleware, and proprietary algorithms.
- Jitian Xingzhou — Jitian Xingzhou is a commercial aerospace company that provides optical main payloads in batches as one of its primary operations.
- Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 489
- Round size: Series A $1.4M–$41M; Series B $8.2M–$58M; Series C $20M–$130M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/7a5aSCUfnr https://t.co/x14hb3jO7O
- Darma — DARMA - Digital Healt
- Heluo New Image — Heluo New Image is a cell treatment platform developer that focuses on iPSC directed differentiation, gene editing, large-scale cell product production, and cell therapy technology development.
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 394
- Round size: Seed $650k–$20M; Angel $425k–$21M; Series A $1.4M–$23M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $130M in 2022
Portfolio highlights
- Ehang — Ehang is a technology enterprise focused on R&D and production in airplane and aircraft field. With the combination of software and hardware techniques, it self-developed the communication and real-time viewing hardware and a smartphone operation system. Its product, Ghost, is accepted as the first truly smartphone app operated intelligentrobot, which is widely used in geographical information surveying, professional television aerial filming, roadshow displaying, disaster rescuing and delivery, surveillance and monitoring, and even expected to play important role in the future logistics areas.Ehang was founded in 2014 by makers from China, America, and Singapore who are enthusiastic about drone flying. The enterprise’s core members graduated from Tsinghua University, Peking University, and Duke University in America.
- ImageDT — ImageDT is a Enterprise services company.
- Futuring Robot — Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios.
Volcanics Venture was founded in May 2016. They identify, invest in, and serve the most promising companies and outstanding entrepreneurs in Internet Innovation, Intelligent Technology and Healthcare industry. Managing Partners Suyang Zhang, Yeshun Dong and Ying Wu have been working closely for years as first-class USD/RMB fund managers.They have more than 60 years of aggregated VC investment and corporate management experience, as well as in-depth understanding of three focused fields. Volcanics Venture brings a powerful combination of global perspective and local experience to investment management, striving to provide sustainable value-added service to their portfolio companies and bring superior return to their limited partners.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 103
- Round size: Seed $350k–$17M; Series A $425k–$21M; Series B $5.7M–$60M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $73M in 2018
Portfolio highlights
- Unisic — Unisic designs and manufactures silicon carbide core power components. Unisic develops sets of products based on silicon carbide and has applied silicon carbide power modules to aviation, new energy power generation, high-end medical care, oil exploration, lighting, new energy vehicles, data centers, and other important fields.
- EVAS Intelligence — EVAS Intelligence is an autonomous driving chip startup. The company was founded by Liu Hui.
- Fengtai Technology — Focusing on industrial information security, Fujian and Taiwan technology mainly provides professional, standard chemical control safety consulting and evaluation services to ensure information security of key industrial information infrastructure and improve security protection solutions. It mainly serves the government, industry customers, designinstitutes, research institutes, institutes, integrators and hardware and software manufacturers. Through visual, process and customized tools and methods, it helps users to carry out effective risk management and reliable operational support. .
Plum Ventures is a venture capital company that aims to encourage young people to become entrepreneurs. It specializes ins providing seed and early-stage investments in the technology, new media, and telecommunications industry. The firm was founded in May 2014 and is based in Changzhou, China.
Show more...Investment focus
- Industry: E-Commerce, Manufacturing, Software
- Stage:Series A, Angel, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 231
- Round size: Seed $1.4M–$10M; Angel $425k–$6M; Series A $1.4M–$28M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Zeta Fusion — Zeta Fusion operates within the technology promotion and application services industry.
- DeepGate Transformation — DeepGate Transformation provides aerospace thermal products by using pyrolytic graphite technology.
- Delta Intelligence Technology — Delta Intelligence Technology is a next-generation embodied intelligence company focused on integrating advanced artificial intelligence with physical systems to create machines that can perceive, learn, and act in the real world.
K2VC (Xianfeng Evergreen) was founded in 2010, focused on early stage investment in technology start-ups in China, focus on promoting change and technological progress, innovative business models and lifestyles.
Show more...Investment focus
- Industry: E-Commerce, Manufacturing, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Japan
Investor stats
- Total investments: 215
- Round size: Seed $1.5M–$14M; Angel $425k–$7M; Series A $1.4M–$50M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $141M in 2018
Portfolio highlights
- Quantex — Quantex is committed to focusing on the next generation of information technology and integrated circuit fields, and is dedicated to the in-depth research and development of 3.2T/6.4T photonic integrated chips (PIC), optical modules and CPO (co-packaged optics) solutions, leading the localization of high-end optical transmission chips.
- Mofeng Technology — Mofeng Technology is a high-tech enterprise specializing in the research and development of polymer materials.
- ChipSense Technology — ChipSense Technology is a semiconductor focused on developing high-performance chips for AI computing infrastructure. The company provides chip solutions that enable perception and efficiency management in AI computing centers, helping optimize resource utilization, operational efficiency, and intelligent management of large-scale AI computingclusters.
Sinopharm Capital is a private equity arm of China National Pharmaceutical Group Corporation that specializes in medical and healthcare, pharmaceuticals, biotechnology, medical devices, healthcare and medical supply, and services for elderly and persons with disability. It seeks to invest in China. Sinopharm Capital was founded in June 2012 and isbased in Shanghai, China.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Canada
Investor stats
- Total investments: 50
- Round size: Seed $2.9M–$16M; Series A $1.4M–$28M; Series B $9.2M–$114M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $150M in 2019
Portfolio highlights
- Metanovas Biotech — Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning.
- Artivila Therapeutics — Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform,providing first-in-class new molecules consistently and efficiently.Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China.
- Jinju Biopharmaceuticals — Jinju Biotechnology is a high-tech enterprise specializing in the research and development of stem cell therapies.
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 278
- Round size: Seed $2.9M–$100M; Series A $1.4M–$43M; Series B $8.5M–$100M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Awomo — Awomo, an AI technology service provider and focuses on the field of Physical AI, dedicated to building foundational models and intelligent systems for robots and the real world.
- Youshu Quantum — Youshu Quantum is a deep-tech startup specializing in quantum computing software, middleware, and proprietary algorithms.
- Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
CASH invests in emerging industries such as information technology and healthcare and focuses on fast-growing businesses in the start-up and growth stage.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 83
- Round size: Series A $1.4M–$30M; Series B $14M–$43M; Series C $30M–$113M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- BOTSINGTECH — BOTSINGTECH is an enterprise specialized in R&D and manufacturing of trackless guided all position crawling welding robot systems.
- Lizheng Technology — Lizheng Technology offers a selection of low-altitude security solutions, drone detection and services through technological advancement and product development.
- SuperMagnetic New Energy — SuperMagnetic New Energy is a cutting-edge innovation center and engineering incubator.
Health Care Investor funding in China at a glance
Stats across 5.9k deals from 5k investors.
Access all 4951 investors in China Health Care startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care Investors in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 4951 investors investing in China Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!